IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025

Trending...
PLEASANTON, Calif., Sept. 12, 2025 ~ Journalist: IASO Biotherapeutics, a leading biopharmaceutical company, has announced promising results of their latest cell therapy for the treatment of Progressive Multiple Sclerosis (PMS). The fully human anti-BCMA CAR-T cell therapy, known as Equecabtagene Autoleucel (Eque-cel), has shown positive outcomes in an independent trial and will be presented at two prestigious academic conferences.

The data from the trial will be disclosed through a poster presentation at the 2025 American Neurological Association (ANA) Annual Meeting and an oral presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. These conferences are highly anticipated events in the medical community and attract top researchers and experts in the field.

The poster presentation will take place on September 15, 2025, at the ANA Annual Meeting in Baltimore, USA. The abstract ID for this presentation is M110. The oral presentation will be held on September 26, 2025, at the ECTRIMS Congress in Barcelona, Spain. The abstract ID for this presentation is ECTRIMS25-1626.

More on Marylandian
The presenter for both presentations will be Professor Chuan Qin from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. This research is based on an investigator-initiated trial led by Professor Wei Wang's team from the Department of Neurology at Tongji Hospital. The trial aims to evaluate the efficacy and safety of Equecabtagene Autoleucel in treating relapsed/refractory antibody-mediated idiopathic inflammatory disorders of the nervous system.

The study included five patients with PMS, including one with primary progressive MS (PPMS) and four with secondary progressive MS (SPMS). The results showed significant improvements in physical function and no new or enlarged lesions were observed on MRI scans.

Specifically, there was a mean improvement in the Expanded Disability Status Scale (EDSS) score from 6.2 at baseline to 5.0 at the last visit. The mean times for the 9-HPT and T25-FW tests also decreased, indicating improved motor function. Additionally, there were no new or enlarged lesions observed on MRI scans.

More on Marylandian
In terms of safety, four out of five patients experienced mild side effects such as transient grade 1 cytokine release syndrome (CRS). No other neurologic toxic effects were observed post-infusion. The only significant side effects were grade ≥3 neutropenia and decreased lymphocyte count, with no occurrences of grade ≥3 anemia or thrombocytopenia.

In conclusion, the results of this trial demonstrate that Equecabtagene Autoleucel is well-tolerated and highly effective in treating progressive MS. This is evidenced by the improvements in physical function and resolution of certain markers in cerebrospinal fluid (CSF). These findings are promising for the future treatment of PMS and provide hope for those living with this debilitating disease.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on Marylandian